|
Q2 FY2026
As of Jul 31, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
|
|---|---|---|---|---|---|---|---|---|---|---|
| Deferred offering costs | ||||||||||
| Cash | ||||||||||
| Other receivable | ||||||||||
| Prepaid expenses | ||||||||||
| Due from Target | ||||||||||
| Total Current assets | ||||||||||
| Cash held in Trust Account | ||||||||||
| TOTAL ASSETS | ||||||||||
| LIABILITIES AND SHAREHOLDERS’ DEFICIT | ||||||||||
| Current liabilities | ||||||||||
| Accrued expenses | ||||||||||
| Accrued offering costs | ||||||||||
| Advance from related party | ||||||||||
| Due to Sponsor | ||||||||||
| Total Current liabilities | ||||||||||
| Deferred underwriting fee | ||||||||||
| Deferred underwriting fee payable | ||||||||||
| TOTAL LIABILITIES | ||||||||||
| Ordinary shares subject to possible redemption; 4,831,265 shares at redemption value of $11.08 and $10.82 per share as of June 30, 2026 and December 31, 2025, respectively | ||||||||||
| SHAREHOLDERS’ DEFICIT | ||||||||||
| Ordinary shares, $0.0001 par value; 200,000,000 shares authorized; 3,512,500 issued and outstanding (excluding 4,831,265 shares subject to possible redemption) as of June 30, 2026 and December 31, 2025 | ||||||||||
| Additional paid-in capital | ||||||||||
| Share subscription receivable | ||||||||||
| Accumulated deficit | ||||||||||
| TOTAL SHAREHOLDERS’ DEFICIT | ||||||||||
| TOTAL LIABILITIES AND SHAREHOLDERS’ DEFICIT |
Loading...
